PRS1 BUDGET IMPACT ANALYSIS OF UMECLIDINIUM VERSUS TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Pulmonary Disease ◽

Healthcare System ◽

Impact Analysis ◽

Budget Impact ◽

Public Healthcare ◽

Chronic Obstructive ◽

System Perspective ◽

Healthcare System Perspective

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Respiratory Research ◽

10.1186/s12931-018-0916-7 ◽

2018 ◽

Vol 19 (1) ◽

Cited By ~ 3

Author(s):

M. T. Driessen ◽

J. Whalen ◽

B. Seewoodharry Buguth ◽

L. A. Vallejo-Aparicio ◽

I. P. Naya ◽

...

Keyword(s):

Cost Effectiveness ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

System Perspective ◽

Healthcare System Perspective ◽

National Healthcare ◽

Effectiveness Analysis ◽

National Healthcare System

Cost-effectiveness and budget impact analysis of smoking cessation interventions in chronic obstructive pulmonary disease patients in Thailand

Tobacco Induced Diseases ◽

10.18332/tid/83780 ◽

2018 ◽

Vol 16 (1) ◽

Author(s):

Ronnachai Kongsakon

Keyword(s):

Smoking Cessation ◽

Cost Effectiveness ◽

Pulmonary Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Chronic Obstructive ◽

PRS17 - BUDGET IMPACT ANALYSIS OF THE USE OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

Value in Health ◽

10.1016/j.jval.2018.09.2411 ◽

2018 ◽

Vol 21 ◽

pp. S406

Author(s):

L.A. Vallejo-Aparicio ◽

A. Huerta

Keyword(s):

Pulmonary Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Chronic Obstructive ◽

PRO36 BUDGET IMPACT ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR HEAMOPHILIA A PATIENTS WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Value in Health ◽

10.1016/j.jval.2019.09.2366 ◽

2019 ◽

Vol 22 ◽

pp. S847 ◽

Cited By ~ 1

Author(s):

P. Souza ◽

G.R. Puopolo ◽

R. Leme-Souza

Keyword(s):

Healthcare System ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Public Healthcare ◽

System Perspective ◽

Healthcare System Perspective ◽

Public Healthcare System

PRS12 Budget Impact Analysis of Tiotropium Bromide Versus Ipratropium Bromide on the Top of Standard Therapy in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) in Russian Federation

Value in Health ◽

10.1016/j.jval.2012.03.296 ◽

2012 ◽

Vol 15 (4) ◽

pp. A53

Author(s):

A. Kulikov ◽

I. Komarov

Keyword(s):

Pulmonary Disease ◽

Russian Federation ◽

Standard Therapy ◽

Ipratropium Bromide ◽

Impact Analysis ◽

Budget Impact ◽

Tiotropium Bromide ◽

Chronic Obstructive ◽

BUDGET IMPACT ANALYSIS OF HOME ADVANCED NON-INVASIVE VENTILATION FOR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Value in Health ◽

10.1016/j.jval.2016.03.690 ◽

2016 ◽

Vol 19 (3) ◽

pp. A299

Author(s):

S. Coughlin ◽

F.W. Peyerl ◽

S.H. Munson ◽

A.J. Ravindranath ◽

Jr. T.L. Lee-Chiong

Keyword(s):

Pulmonary Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Chronic Obstructive ◽

Invasive Ventilation ◽

Non Invasive ◽

Non Invasive Ventilation

Budget Impact Analysis of Indacaterol/Glycopyrronium in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) in Colombia

Value in Health ◽

10.1016/j.jval.2017.08.2662 ◽

2017 ◽

Vol 20 (9) ◽

pp. A888

Author(s):

A Patino ◽

E Karpf ◽

D Londoño

Keyword(s):

Pulmonary Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Chronic Obstructive ◽

PRS13 A Budget Impact Analysis of Indacaterol for the Treatment of Chronic Obstructive Pulmonary Disease in Colombia

Value in Health ◽

10.1016/j.jval.2012.03.297 ◽

2012 ◽

Vol 15 (4) ◽

pp. A53

Author(s):

L.F. Giraldo ◽

J.G. Ariza ◽

T. Acosta ◽

J.F. Pinzon

Keyword(s):

Pulmonary Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Chronic Obstructive ◽

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Respiratory Research ◽

10.1186/s12931-019-0985-2 ◽

2019 ◽

Vol 20 (1) ◽

Author(s):

M. T. Driessen ◽

J. Whalen ◽

B. Seewoodharry Buguth ◽

L. A. Vallejo-Aparicio ◽

I. P. Naya ◽

...

Keyword(s):

Cost Effectiveness ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

System Perspective ◽

Healthcare System Perspective ◽

National Healthcare ◽

Effectiveness Analysis ◽

National Healthcare System

Budget Impact Analysis of Aclidinium Bromide In The Treatment of Chronic Obstructive Pulmonary Disease

Value in Health ◽

10.1016/j.jval.2016.09.1180 ◽

2016 ◽

Vol 19 (7) ◽

pp. A550

Author(s):

R Yagudina ◽

A Kulikov ◽

E Makarova

Keyword(s):

Pulmonary Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Chronic Obstructive ◽

Aclidinium Bromide